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Speedel Staunches the Renin Cascade at Its SourceHypertension gives no warning
signs. Left untreated, it can lead to
kidney and heart disease, retinal
damage, and stroke. Its root causes
are mostly unknown. About 190 mil-
lion people in developed countries
suffer from hypertension. The Amer-
ican Heart Association estimates
nearly one in three U.S. adults have
high blood pressure and that over
a third of them do not effectively
control it.
One of the key regulators of blood
pressure is the renin angiotensin
system (RAS). The RAS cascade is
initiated by renin, a protease pro-
duced by the kidneys that cleaves
the peptide angiotensinogen, con-
verting it to angiotensin I. Angioten-
sin II is formed from angiotensin I
in a reaction catalyzed by angioten-
sin-converting enzyme (ACE), which
spurs blood vessels to contract and
increases vascular resistance, rais-
ing blood pressure. Blocking either
the formation or the action of angio-
tensin II is considered to be an effec-
tive way to control hypertension.
The existence of the renin path-
way was first theorized in 1898 by
Robert Tiegerstedt, a physiologist
at the Karolinska Institute who ex-
perimented on rabbit kidneys. Renin
catalyses the rate-limiting (or bottle-
neck) step of the RAS chain [1], so
renin inhibitors stop the cascade
cold. ‘‘The advantage of blocking
the biological pathway at the very
beginning is that there is no down-
stream molecule interfering with
anything,’’ said Dr. Jessica Mann,
medical director at Speedel (http://
www.speedel.com) a Swiss biotech
company. Speedel, in conjunction
with Novartis, will be the first to
produce a new oral renin-inhibiting
antihypertensive drug, SPP100, or
aliskiren.
‘‘Basically, when you treat hyper-
tension, the only thing you treat is
a couple of figures,’’ said Mann.
‘‘And you want those figures to
reach a magic number.’’ (The defini-
tion of hypertension is 140/90 Hg
[systolic/diastolic]) Mann added,‘‘People don’t die of high blood
pressure on its own. People die of
the long-term effects of high blood
pressure on their hearts, their kid-
neys, and their brains.’’ According
to Mann, despite great interest in re-
nin inhibitors, pharmaceutical com-
panies virtually abandoned them in
the 1990s because they were large,
complicated molecules, expensive
to produce, and their bioavailability
and potency were too low to be
effective.
Speedel, in conjunction
with Novartis, will be the
first to produce a new
oral renin-inhibiting anti-
hypertensive drug
The Pit Viper Effect
The dangers associated with hyper-
tension were recognized in the
1930s, but the first effective oral
antihypertensive agents, diuretics,
only appeared in the 1950s. Di-
uretics reduce blood pressure, in
part, by increasing renal sodium ex-
cretion, thereby reducing the overall
fluid volume in the body. They are
still used today, both as first-line
therapies and in combination with
other drugs. Beta blockers were
introduced in the 1970s, and cal-
cium channel blockers in the 1980s.
Beta blockers lower blood pressure
by reducing the heart’s overall
blood pumping capacity; they also
decrease renin release from the
kidney. Angiotensin-converting en-
zyme (ACE) inhibitors were devel-
oped in the mid 70s, as an indirect
result of earlier experiments on
the blood pressure-lowering effects
of Brazilian pit viper venom. The
first orally active ACE inhibitor, cap-
topril, was approved by the FDA in
1981. Calcium channel blockers and
ACE inhibitors both reduce blood
pressure through their vasodilatory
effects.Angiotensin receptor type II
blockers (ARBs) were first marketed
in the U.S. in the mid 90s. ARBs
inhibit the vasopressive effects of
angiotensin II, the principal mediator
of RAS downstream of renin produc-
tion, by selectively blocking the AT1
receptors on the surface of target
cells. By interfering with feedback
inhibition, they increase angiotensin
II levels. All or most of the deleteri-
ous effects of angiotensin II stimula-
tion are mediated through the AT1
receptor. In most patients, a single
antihypertensive agent does not
succeed in reducing blood pressure
to target levels, so various drug
combinations are used, often in-
cluding a low-dose diuretic. The
side effects of antihypertensive
agents vary: ARBs have the fewest
side effects and, in most studies,
exhibit a placebo-like tolerability
profile.
Call Back When the Molecule
Shapes Up
Speedel, now numbering over 70
employees, was founded in 1998
as an indirect result of the merger
between Ciba-Geigy and Sandoz
that formed Novartis. Dr. Alice Hux-
ley was in charge of the early devel-
opment of aliskiren at Ciba-Geigy,
but the Novartis management de-
cided to discard the compound, pri-
marily because of its high cost of
manufacturing. Novartis had other
hypertension candidates at the time,
including Diovan (valsartan). In 1999,
Huxley and her colleagues licensed
aliskiren under a ‘‘call back option,’’
meaning that if it successfully
passed Phase II trials, Novartis
would license it back for Phase III
tests and commercialization.
‘‘The synthesis of aliskiren was
a major issue,’’ said Dr. Peter Herold,
director of chemistry at Speedel,
whose team did extensive molecular
modelingandcrystallographicstruc-
ture analysis to optimize the drug.
‘‘Aliskiren has four chiral centers
in the molecule. Mathematically,
you have 16 possibilities. From
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of the day, only one is the one you
want, as the others don’t fit in the en-
zyme.’’
Aliskiren was licensed back by
Novartis in 2002 and is commercial-
ized under the trade name Tekturna.
Novartis recently announced favor-
able phase III data covering over
7000 patients with mild-to-moder-
ate hypertension in the U.S., E.U.
and Japan who were treated for
a period between 6 and 52 weeks.
Aliskiren was also tested in conjunc-
tion with a diuretic (HCTZ), a calcium
channel blocker (amlodipine), and
an ACE inhibitor (ramipril). The FDA
accepted aliskiren for regulatory
review in April 2006.
‘‘The data, at least what I’ve seen
of it, looks pretty clean,’’ said
Dr. Alan Gradman, chief, division of
cardiovascular diseases, the West-
ern Pennsylvania Hospital, who was
involved with some of the aliskiren
clinical studies. According to Grad-
man, aliskiren lowers blood pres-
sure and has a comparable side
effect profile to an ARB. ‘‘It is not
just about the hypertension and
hemodyamics, it is also about inhib-
iting end organ damage effects that
occur with arteriosclerosis and left
ventricular hypertrophy and so on,’’
said Gradman, ‘‘At this point in
time there is very little data on the
effects of aliskiren on any of these
end organ effects. And part of the
problem is that you cannot really
study this well in animal models as
the compound is very specific for
human renin. What is interesting
about renin inhibitors is that they
antagonize the renin angiotensin
system through a different phar-
macologic mechanism than ACEs
and ARBs, so the question is what
effect they will have on the end
points?’’
Speedel says that aliskiren, unlike
ACE inhibitors and ARBs, inhibits
renin, i.e., plasma renin activity
(PRA), a surrogate marker for heart
attacks and kidney disease. Grad-
man pointed out that Novartis is
now testing intermediate end points
such as proteinuria (protein in the
urine) to see if aliskiren attenuates
the progression of kidney disease
in patients. Novartis is also looking
at LVH regression (left ventricular
hypertrophy, the thickening of the
heart muscle that occurs as a result
of the heart having to contractagainst higher pressures) for cardio-
vascular disease, but it will be diffi-
cult to see results without specific
trials measuring actual disease pro-
gression as an endpoint. Novartis is
also hypothesizing that combining
aliskiren with an ARB might provide
long-term organ protection because
there is no activation of RAS.
Speedel’s inaugural strategy was
to license promising cardiovascular
or metabolic drug candidates from
other companies, improve them, and
then license them back to pharma.
However, around 2002, Speedel
started their own internal develop-
ment program, Speedel Experi-
menta, now comprising 40 people.
Speedel financed itself by raising
U.S. $64 million through a sale of
500,000 treasury shares in March
2006. The company previously
raised U.S. $183 million from private
placements and two rounds of eq-
uity financing. Milestone revenues
have totaled U.S. $44 million so far.
Speedel is traded on the Swiss
stock exchange.
Aside from aliskiren, Speedel has
three other classes of renin inhibi-
tors: the 600 series in-licensed from
Roche; the 800 series, stemming
from a collaboration with Locus
Pharmaceuticals, now in preclinical
testing; and the 1100 series, devel-
oped internally. Speedel is also de-
veloping SPP301, an endothelin A
receptor antagonist for diabetic
neuropathy that is in Phase III trials,
and SPP200, an anticlotting agent
licensed from Abbott for vascular
graft occlusion, now in Phase II trials.
Renin Inhibitors Take Off
Speedel faces competition from
rival Swiss company, Actelion
(http://www.actelion.com) working
with Merck on a renin inhibitor that
entered human clinical trials in July
2006. ‘‘Aliskiren is still a substrate
peptidomimetic, whereas Actelion’s
compounds are nonsubstrate ana-
logs based on templates found orig-
inally by random screening.’’ said
Walter Fischli, Ph.D., head, drug dis-
covery, biochemistry, and molecular
biology at Actelion, ‘‘Before Acte-
lion’s breakthrough, pharmaceutical
companies large and small failed
to turn peptidomimetics into highly
bioavailable renin inhibitors. The
implications of low bioavailable
compounds are usually high doses
and variable pharmacologic results,with the ultimate question [being]
whether a full blockade of the sys-
tem can be achieved at all.’’
Vitae Pharmaceuticals, (http://
www.vitaepharma.com), a private
company based in Fort Washington,
PA, also has a renin inhibitor in
preclinical development for hyper-
tension in conjunction with Glaxo-
SmithKline. The published literature
on renin inhibitors contains contri-
butions from other interested phar-
maceutical companies, including
Pfizer.
‘‘Most of the renin inhibitors de-
veloped over the past two decades
were large molecules and couldn’t
get through the GI tract,’’ said Dr.
Randall Zusman, director of hyper-
tension and vascular medicine at
Massachusetts General Hospital.
‘‘Aliskiren is a complex molecule,
but it has sufficient bioavailability
to inhibit renin activity in vivo, in
doses that do not induce adverse
side effects. Clinicians will be com-
paring these new drugs principally
to ACE inhibitors and ARBs. Is this
new strategy more effective than
what we have available, with fewer
side effects? A point in renin inhibi-
tor-based drugs’ favor is that they
have a very long half life (aliskiren
lasts approximately 40 hr). But until
they are used by a larger number of
patients, we don’t really know a
whole lot. The promise of this drug
is to disrupt the [renin] cascade
very early and be very complete in
its inhibitory effect.’’
A century after Tiegerstadt
ground up rabbit kidneys and identi-
fied RAS, treating hypertension,
though considerably progressed, is
far from perfected. Time will tell
whether renin inhibitors fulfill their
promise, but as people age and
waistlines spread, increasing car-
diovascular and metabolic diseases
are sure to maintain the flow of
demand for new drugs.
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